Thompson Davis & CO. Inc. Takes $391,000 Position in AbbVie Inc. $ABBV

Thompson Davis & CO. Inc. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,109 shares of the company’s stock, valued at approximately $391,000.

Other institutional investors have also added to or reduced their stakes in the company. Capital Investment Counsel Inc increased its position in AbbVie by 97.2% during the 2nd quarter. Capital Investment Counsel Inc now owns 2,079 shares of the company’s stock worth $386,000 after buying an additional 1,025 shares during the period. ABN Amro Investment Solutions bought a new stake in shares of AbbVie in the second quarter valued at about $12,597,000. Cherokee Insurance Co bought a new position in AbbVie during the second quarter worth about $1,856,000. Candriam S.C.A. increased its position in AbbVie by 43.4% during the second quarter. Candriam S.C.A. now owns 575,792 shares of the company’s stock worth $106,883,000 after acquiring an additional 174,294 shares during the period. Finally, Impax Asset Management Group plc acquired a new stake in AbbVie in the 2nd quarter worth about $990,000. 70.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Daiwa Capital Markets raised AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price target on the stock in a research report on Thursday, August 7th. Wells Fargo & Company raised their price objective on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Hsbc Global Res downgraded AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Finally, Morgan Stanley increased their target price on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Stock Performance

NYSE:ABBV opened at $235.12 on Thursday. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The stock’s 50-day simple moving average is $224.10 and its 200 day simple moving average is $203.43. The firm has a market capitalization of $415.54 billion, a PE ratio of 111.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the firm earned $3.00 earnings per share. The business’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.9%. AbbVie’s payout ratio is presently 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.